Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Evolution of H5N1 avian influenza viruses in Asia.

World Health Organization Global Influenza Program Surveillance Network.

Emerg Infect Dis. 2005 Oct;11(10):1515-21.

2.

Development of nonhuman adenoviruses as vaccine vectors.

Bangari DS, Mittal SK.

Vaccine. 2006 Feb 13;24(7):849-62. Epub 2005 Sep 23. Review.

3.

Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.

Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH.

J Virol. 2005 Nov;79(22):14161-8.

4.

Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines.

Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG.

Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12915-20. Epub 2005 Aug 23.

5.

Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics.

Tian G, Zhang S, Li Y, Bu Z, Liu P, Zhou J, Li C, Shi J, Yu K, Chen H.

Virology. 2005 Oct 10;341(1):153-62.

6.

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Nabel GJ.

Vaccine. 2005 Nov 16;23(46-47):5404-10. Epub 2005 Jun 13.

PMID:
16011865
7.

Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model.

Lipatov AS, Webby RJ, Govorkova EA, Krauss S, Webster RG.

J Infect Dis. 2005 Apr 15;191(8):1216-20. Epub 2005 Mar 14.

8.

Probable person-to-person transmission of avian influenza A (H5N1).

Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, Zaki SR, Thawatsupha P, Chittaganpitch M, Khontong R, Simmerman JM, Chunsutthiwat S.

N Engl J Med. 2005 Jan 27;352(4):333-40. Epub 2005 Jan 24.

9.

Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture.

Bangari DS, Shukla S, Mittal SK.

Biochem Biophys Res Commun. 2005 Feb 18;327(3):960-6.

PMID:
15649439
10.

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC.

Vaccine. 2005 Jan 11;23(8):1029-36.

PMID:
15620476
11.

Avian influenza--a challenge to global health care structures.

Hien TT, de Jong M, Farrar J.

N Engl J Med. 2004 Dec 2;351(23):2363-5. No abstract available.

PMID:
15575048
12.

Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.

Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, Mittal SK.

Cancer Gene Ther. 2004 Nov;11(11):757-66.

PMID:
15359289
13.

Update: influenza activity--United States and worldwide, 2003-04 season, and composition of the 2004-05 influenza vaccine.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2004 Jul 2;53(25):547-52.

14.

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.

Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC.

Virus Res. 2004 Jul;103(1-2):91-5.

PMID:
15163495
15.

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI, Webster RG.

Lancet. 2004 Apr 3;363(9415):1099-103.

PMID:
15064027
16.

Avian influenza A(H5N1).

[No authors listed]

Wkly Epidemiol Rec. 2004 Feb 13;79(7):65-70. English, French. No abstract available.

PMID:
15024851
17.

Re-emergence of fatal human influenza A subtype H5N1 disease.

Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, Ng TK, Chan KH, Lai ST, Lim WL, Yuen KY, Guan Y.

Lancet. 2004 Feb 21;363(9409):617-9.

PMID:
14987888
18.

Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response.

Sailaja G, HogenEsch H, North A, Hays J, Mittal SK.

Gene Ther. 2002 Dec;9(24):1722-9.

19.

Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.

Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, Renshaw M, Arpino R, Tamane A, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D.

Cell Immunol. 2001 Aug 1;211(2):143-53.

PMID:
11591118
20.

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC.

Lancet. 2001 Jun 16;357(9272):1937-43.

PMID:
11425416
Items per page

Supplemental Content

Write to the Help Desk